Document ID: chunk:federal_register_of_legislation:F2020C00216:reg:9:p2
Version: federal_register_of_legislation:F2020C00216
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 9812–11714

of the eye; or
                Note:    unprotected eye and whole body PUVA are defined in the Schedule 1 - Dictionary.
(b)          having at least two episodes of photokeratitis of the affected eye, where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the eye;
                Note:   photokeratitis is defined in the Schedule 1 - Dictionary.
(8)          for conjunctival melanoma of the eye only, receiving a conjunctival transplant to the affected eye before the clinical onset of malignant neoplasm of the eye;
(9)          for squamous cell carcinoma of the cornea or the conjunctiva only:
(a)          acquiring persistent infection of the epithelium of the conjunctiva of the affected eye with a specified human papilloma virus (HPV) before the clinical onset of malignant neoplasm of the eye;
                Note:   specified human papilloma virus (HPV) is defined in the Schedule 1 - Dictionary.
(b)          having ultraviolet radiation exposure from whole body PUVA therapy to the unprotected eye, where:
(i)            the first PUVA treatment commenced at least five years before the clinical onset of malignant neoplasm of the eye; and
(ii)         at least 25 PUVA treatments were administered before the clinical onset of malignant neoplasm of the eye; or
                Note: unprotected eye and whole body PUVA are defined in the Schedule 1 - Dictionary.
(c)          being treated with voriconazole for a continuous period of at least the four weeks before the clinical onset of malignant neoplasm of the eye;
(10)      for squamous cell carcinoma of the conjunctiva only, having an ocular prosthesis in an anophthalmic socket of the affected eye for more than ten years before the clinical onset of malignant neoplasm of the eye;
(11)      inability to obtain appropriate clinical management for malignant neoplasm of the eye.